Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 6, 2006, Pages 965-971

  Palacios, Rosario ^a   Aguilar, Isabel ^a   Hidalgo, Ana ^a   Santos, Jésus ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Antiretroviral; Backbone; Didanosine; Efavirenz; Entricitabine; HAART; Llamivudine; Naive; Once daily

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG COST; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FATTY LIVER; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; NAUSEA; NEUROTOXICITY; PANCREATITIS; PATIENT COMPLIANCE; POLYNEUROPATHY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DIDANOSINE; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; OXAZINES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33846012522     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.6.965     Document Type: Review

References (50)

1. Fischl MA, Richman DD, Grieco MH et al. The efficacy of 3′-azido-3′ deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
2. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviraltherapy. HIV Med. 6(Suppl. 2), 1-61 (2005).
3. Iribarren JA, Labarga, P, Rubio R et al. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm. Infecc. Microbiol. Clin. 22, 564-642 (2004).
4. Bartlett J, Fath M, DeMasi R, Quinn J, Hermes A, Rousseau F. An Updated Meta-analysis of Triple Combination Therapy in Antiretroviral-naive HIV-infected Adults. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, Boston MA, USA, 2005. Abstract 586.
5. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev. Anti Infect. Ther. 5, 671-684 (2004).
6. Clay PG, Dong BJ, Sorensen SJ, Tseng A, Romanelli F, Antoniou T. Advances in human immunodeficiency virus therapeutics. Ann. Pharmacother. 40, 704-709 (2006).
7. Vivet-Boudou V, Didierjean J, Isel C, Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci. 63, 163-186 (2006).
8. Gallant JE, Gerondelis PZ, Wainberg MA et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir. Ther. 8, 489-506 (2003).
9. Jones R, Sawleshwarkar S, Michailidis C et. al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 6, 396-402 (2005).
10. Maggiolo F, Miggliorino, M, Maserati R et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir. Ther. 6, 249-253 (2001).
11. Landman R, Schiemann R, Thiam S et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 17, 1017-1022 (2003).
12. Maggiolo F, Ripamonti D, Gregis G et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir. Ther. 8, 339-346 (2003).
13. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292, 180-189 (2004).
14. Molina JM, Ferchal F, Racinan C et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J. Infect. Dis. 182, 599-602 (2000).
15. DeJesus E, Ward D, Cohen C et al. Efficacy and safety of a once-daily efavirenz (EFV)-based regimen for treatment of naive HIV subjects: 96 week results from the DART study. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference. November 17-20, 2005. Dublin, Ireland. Abstract PE 7.3/3.
16. Maggiolo F, Ripamonti D, Migliorino G et al. Three once-a-day regimens as first-line HAART. Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005, Rio de Janeiro, Brazil. Abstract WePe12.2C04.
17. Maitland D, Moyle G, Hand J et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19, 1183-1188 (2005).
18. Santos J, Palacios R, López M et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: the VESD study. HIV Clin. Trials 6, 320-328 (2005).
19. Gallant JE, Staszewki S, Pozniak AL et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-ycar randomized trial. JAMA 292, 191-201 (2004).
20. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
21. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39, 1038-1046 (2004).
22. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 356, 1423-1430 (2000).
23. Walker UA. Update on mitochondrial toxicity: where are we now? J. HIV Ther. 8, 32-35 (2003).
24. Cherry CL, Nolan D, James IR et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 42, 435-440 (2006).
25. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J. Hepatol. 44(Suppl. 1), S119-S125 (2006).
26. Moreno A, Quereda C, Moreno L et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir. Ther. 9, 133-138 (2004).
27. Laguno M, Milinkovic A, de Lazzari E et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir. Ther. 10, 423-429 (2005).
28. Hsu RK, Wainberg MA. Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing. J. Acquir. Immune Defic. Syndr. 35(Suppl. 1), S13-S21 (2004).
29. Kempf D, King M, Bernstein B et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189, 51-60 (2004).
30. Eton JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/ zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 10(Suppl. 5), S11-S19 (1996).
31. Melby T, Tortell S, Thorborn D et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001, Chicago, Illinois, USA. Abstract 448.
32. Farthing C, Kharlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. July 13-16, 2003, Paris, France. Abstract 43.
33. Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. Program and abstracts of the 11th Conference on Retrovirus and Opportunistic Infections. February 8-11, 2004, San Francisco, CCA, USA. Abstract 52.
34. Ruane P, Luber A, Akil B et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. Program and abstracts ofthe 2nd IAS Conference on HIV Pathogenesis and Treatment. July 13-16, 2003, Paris, France. Abstract 582.
35. D'Aquila RT, Schapiro JM, Brun-Vezinet F et al. Drug resistance mutations in HIV-1. Top. HIV Med. 11, 92-96 (2003).
36. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37, 113-128 (2003).
37. Lanier R, Irlbeck D, Ross L et al. Prediction of NRTI options by linking reverse transcriptase genotypes to phenotypic breakpoints. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston, MA, USA. Abstract 586.
38. Marcelin AG, Flandre P, Pavie J et al. AI454-176 Jaguar Study Team. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother. 49, 1739-1744 (2005).
39. Flandre P, Marcelin AG, Pavie J et al. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir. Ther. 10, 479-487 (2005).
40. Knobel H. [Quality of life, satisfaction, adherence and effectivity to antiretroviral treatment]. Enferm. Infecc. Microbiol. Clin. 23, 579-580 (2005).
41. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21-30 (2000).
42. Moyle G. Once-daily therapy: less is more. Int. J. STD AIDS 14(Suppl. 1), 1-5 (2003).
43. Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin. Trials 4, 193-201 (2003).
44. Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS 19, 9-18 (2005).
45. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J. Acquir. Immune Defic. Syndr. 36, 808-816 (2004).
46. Pulido F, Ribera E, Moreno S et al. Once-daily antiretroviral therapy: Spanish Consensus Statement. J. Antimicrob. Chemother. 5, 808-818 (2005).
47. Knobel H, Guelar A. [Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen]. Enferm. Infecc. Microbiol. Clin. 22, 106-112 (2004).
48. Palacios R, del Arco A, Grana M et al. Adherence and quality of life with a once-daily antiretroviral regimen with didanosine (ddI), lamivudine (3TC) and efavirenz (EFV) in naïve patients. The VESD study. Abstract WePe12.2C05. 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005. Río de Janeiro, Brazil.
49. Merito M, Pezzotti P, for the ICONA Study Group. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients Evidence from the ICONA cohort. Eur. J. Health Econ. 1, 30-36 (2006).
50. Colebunders R, Florence E, Lynene L, Bouckenooghe A. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives? Int. J. STD AIDS 14, 1-5 (2003).